UroGen Pharma Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+16.31%
vs ±16.0% implied · ×1.02
shaded = implied · ▲▼ = realized
UroGen Pharma has 6 disclosed suppliers and 0 disclosed customers in SEC filings.
UroGen Pharma Ltd.
32.70
SentenceIn November 2019, we entered into a license agreement with Agenus, pursuant to which Agenus granted us an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus's intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary monoclonal antibody of Agenus known as AGEN1884 (zalifrelimab), an anti-CTLA-4 antagonist, for the treatment of cancers of the urinary tract via intravesical delivery.
SentenceFor example, in August 2020, we announced that the Phase 2 APOLLO trial of BOTOX/ RTGel for the treatment of overactive bladder, which was conducted by Allergan Pharmaceuticals Limited ("Allergan"), did not meet the primary endpoint.
URGN 10-Kaccession 0001437749-26-006234
SentenceWe currently rely on Cenexi-Laboratories Thissen s.a. for the bulk mitomycin contained in Jelmyto and Zusduri .
URGN 10-Kaccession 0001437749-26-006234
SentenceOn February 14, 2025 (the "Closing Date"), we entered into an asset purchase agreement (the "IconOVir Agreement") with IconOVir Bio, Inc. ("IconOVir"), pursuant to which we purchased and acquired certain assets of IconOVir (the "Transferred Assets"), including UGN-501 (formerly ICVB-1042) and certain contracts, intellectual property rights, regulatory applications, submissions and registrations, and data and other rights related thereto, and assumed certain liabilities and obligations of IconOVir arising under certain contracts of IconOVir acquired by us.
URGN 10-Kaccession 0001437749-26-006234
SentenceWe depend on Isotopia Molecular Imaging Ltd. as our single contracted suppliers for the hydrogel contained in Jelmyto and Zusduri .
URGN 10-Kaccession 0001437749-26-006234
—
Expected move
Inputs8Q avg ±9.6%·×1.34·rich
straddle ±15.7%
spot 32.72exp Nov 20ATM strike 33ATM straddle 6.05IV 96%